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HIV INFECTION EPIDEMIOLOGY  
In 1981 Center for Disease Control (CDC) di Atlanta (USA) 
detected the presence of a rare and severe variant pneumonia due to 
Pneumocystis carinii (today recalled Pneumocystis jiroveci), a 
commensal protozoa, in young homosexual individuals.1  
Simultaneously, there were many clinical reports of a rare vascular 
cancer in young individuals, previously diagnosed only in elderly 
subjects, called Kaposi’s sarcoma. In 1983, researchers from Pasteur 
Institute identified the virological agent as a retrovirus related to 
HTLV-1 (Human T-Lymphotropic virus type 1), and in 1985 it was 
possible to detect the presence of specific antibodies to permit to 
identify its presence on blood samples by blood donors. At the 
beginner, the virus was recalled LAV and HTLVIII, and finally Human 
Immunodeficiency Virus (HIV) in 1986 according to WHO. HIV was 
identified as the cause of AIDS, acquired immunodeficiency 
syndrome: a complex of different diseases characterized by a deep 
immune-depression resulting in a vast range of clinical settings2.  It 
was also proved that the HIV progenitor is a primates retrovirus: 
probably multiple episodes of infection between monkeys and 
humans, in distant african areas during the first decades of 1900, 
determined the development of the infection from rural to urban 
zones through the mucosal/skin exposition from contaminated 
animal biological materials.3 Indeed, both serotypes, HIV-1 and HIV-
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2, respectively, are correlates to SIVcpz (as guest Pantroglodytes 
troglodytes, a kind of Chimpanzee) and to SIVsm (as guest 
Cercocebus torquato atys, other Chimpanzee variant located to west 
Africa area as Guinea Bissau, Sierra Leone, Nigeria and Senegal, with 
a total prevalence of 1% with low transmission efficacy and long 
incubation period). UNAIDS reports 2012 evaluated about 35,3 
millions of people living with HIV with an incidence of 2,3 millions of 
new infections per year and 1,6 millions of deaths due to AIDS, 
whose 75% in sub-saharian Africa regions.  Analysing the last years, 
we can assume that the global prevalence is stable although the 
number of HIV living people increased due to the improvement of life 
expectancy in western countries; moreover, the reduction of deaths is 
due to both the therapies and the reduction of annual incidence. It is 
important to note that there are two different clinical backgrounds of 
HIV according the modality of transmission: epidemic model (model 
I), located in sub-saharian areas, that is essentially heterosexual and 
paediatric transmission; a partial/selected modality in western 
countries (model II) that includes intravenous drug users, “sex 
workers” and their sexual partners, homosexuals and heterosexuals; 
and a further model (model III) most typical in areas with low HIV 
transmission, with a mix of the first two models. Some envelope 
glicoproteins show 4 distinct groups: M (mayor), O (outlier), N (Non 
M-Non O) e P. The M group is the most diffused on the world, with 9 
types (A-B-C-D-F-G-H-J-K) and 6 sub-types (A1, A2, A3, A4, F1, F2); 
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often the different types are located in different areas; for example B-
type in USA and western Europe, E in Thailand; C in India, Ethiopia 
and southern Africa4. Risk groups are intravenous drug users, 
homosexuals and “sex workers” with their partners.5 Transmission 
infection acquisition occurs through sexual transmission (both 
homosexual and heterosexual), parenteral transmission (blood 
transfusion o related, syringes use…) and vertical transmission.6,7. 
Mediterranean countries, as Italy, showed a model II transmission 
modified with high level of infection through intravenous drug users 
and vertical transmission, with an increase of the infection until to 
1995, and subsequently reduction until 2000. In 2012 there were 
64.898 cumulative AIDS cases with a stable incidence per year of 
3853 new infections, 6.5 per 100.000 residents, with a majority 
prevalence of heterosexual modality, located especially in northern 
regions of the country as Liguria, Veneto, Lombardia, Toscana and 
Emilia Romagna regions2. During the last years there were an 
increase of homosexual transmission, especially in very young 
subjects, determining the homosexual group as the majority 
epidemiological group today, as observed in other western countries8; 
although the incidence of these new people very young infected, the 
median age increased during the last 10 years according analyses 
from ICONA (Italian COhort of antiretroviral Naïve patients). 
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HIV INFECTION ETIOLOGY 
Family Retroviridae: 80-100 nm with envelope, RNA genome 
with 2 copies of the single-stranded RNA and 3 enzymes: reverse 
transcriptase, integrase and protease. The reverse transcriptase 
permits the retrotrascription from RNA to complementary DNA 
(cDNA); the integrase enzyme is essential for the integration of the 
viral cDNA to the cell nucleus; the protease works during the final 
steps of the viral replication cycle.  
Retroviridae family includes two sub-families:  
• Spuma-retrovirinae9 
• Ortho-retrovirinae 
The latter includes 6 genera: Α-retrovirus, Β-retrovirus, Γ-retrovirus, 
Delta-retrovirus, Epsilon-retrovirus e Lentivirus.  
HIV-1, HIV-2 and SIV are all Lentivirus genus virus. The HIV-1 core 
includes p24, p7/p9, the two copies of RNAand the 3 enzymes. The 
superficial part of the core includes p17  (a matrix protein) and other 
2 glicoproteins: gp120 and gp41. The HIV-genome is 9,7 kb and it is 
made by 3 genes: gag, pol and env. Furthermore, there are other 6 
optional genes: tat, rev, vif, nef, vpr, vpu with different functions10. It 
is important to note that HIV presents a high level of genetic 
heterogeneity among different geographic areas and in the same 
individual too11; see Fig.1A and 1B. 
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HIV structure above (Fig 1A); HIV structure and genome below (Fig 1B) 
10 
 
HIV INFECTION CLINICAL SETTING  
NATURAL HISTORY 
After the entry of the virus there are 3 phases:  
• primary infection  
• latency period  
• advanced symptomatic stage  
Primary infection is constituted by both acute clinical syndrome and 
increase of peripheral blood markers. During acute phase it is 
possible to observe the presence of fever, sore throat, asthenia, 
linphadenomegaly, arthromyalgia, nausea, vomit, diarrhoea, 
hepatosplenomegaly, skin rash. During this first phase, HIV 
replicates until 107 copies (cp)/ml with a significant and improvise 
reduction of CD4 T cell count; later some weeks, the immune system 
develops an antiviral response which determines a viral load decay, 
clinical setting resolution and an almost complete immunologic 
recovery12. During this first symptomatic period it is possible to 
detect a subsequent and slow significant reduction of CD4+ T cells 
(50-70 cells/year as CD4 T cells count at blood level) and an increase 
in CD8+ T cells lymphocytes13. Due to the presence of specific marker 
and after 10 days the viral introduction, it is possible to distinguish 
the acute infection among 6 acute stages according to Fiebig 
classification: Fiebig-I with only HIV-RNA detection (viral load, VL), 
Fiebig-II with VL + p24 antigen detection (possible with 4th generation 
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test), Fiebig-III with VL + P24 + Elisa IgM antibodies reactive (all these 
3 stages with Western Blot (WB) negative), Fiebig-IV with 
VL+p24+Elisa+ WB indeterminate, Fiebig-V with VL+p24+Elisa+ WB 
positive without p31 band and finally Fiebig-VI with VL+p24+Elisa+ 
WB positive in association to p31 band too (within 6 months it is 
possible to conclude the acute phase of HIV)14. After the introduction 
of the steady-state, there is a balance between the creation and the 
destruction of new cells, with a long duration of 8-12 years, 
characterized by this distinct and slow decay of the CD4 T cells 
number and by a function alteration of immune system, with an 
important role of CD8 T cells to control the viral replication, without 
viral eradication, due to the presence of a vast viral reservoir6,15. Also, 
it is possible to detect the viral replication at lymphoid level as HIV-
RNA: here, the virus determines a complete rearrangement of the 
lymphoid tissues16.  When the immune system shows a deep 
deterioration, patients start to develop a symptomatic clinical stage of 
AIDS: at beginner with constitutional not specific symptoms, later 
with the onset of opportunistic infections (OI), especially with CD4 T 
cells number below 200/µl, that determine the majority cause of 
death due to HIV (see Fig. 2). During AIDS stage, it is possible to 
detect an increase in virological parameters of viral replication both 
lymph node and peripheral blood6 (Fig. 3A and 3B).  
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Fig 2: natural history of HIV infection 
 
 
Fig 3A and 3B: Fiebig classification 
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OPPORTUNISTIC INFECTIONS  
Simultaneously the reduction of CD4 T cells count, 
opportunistic infections become available through the develop of 
infections and neoplastic disorders. Different etiologic agents can 
determine different clinical settings. In 1992, CDC of Atlanta modified 
the previous classification (1987) according two parameters: clinical 
categories (number 3: A,B and C) and CD4 T cell count (number 3 
ranges: 1,2 and 3). This last CDC classification system is different 
from WHO classification; indeed the CDC classification emphasizes 
the importance of CD4 lymphocyte testing in clinical management of 
HIV infected individuals, creating a matrix of 9 exclusive categories. 
The number indicates different ranges of CD4 T cell count: “1” with 
CD4 > 500 cell/mmc, “2” with CD4 T cells count between 200 and 
500, “3” with CD4 T cells count < 200. The category “A” includes: 
either the asymptomatic HIV infection, either persistent generalized 
lymphoadenopathy as well as the acute primary illness; the category 
“B” includes all symptomatic conditions not included in category A 
and C; the category “C” includes 20 AIDS events. It is possible to 
consider an AIDS stage all people with HIV category C (C1, C2 and 
C3) and all people with CD4 T cells number below 200 (A3, B3 and 
the previous mentioned category C3). It is always AIDS diagnosis for 
some opportunistic disorders: Candidiasis (esophageal, trachea and 
bronchi), Cryptococcosis extrapulmonary, Cryptosporidiosis chronic 
intestinal (with symptoms >1 month), CMV retinitis or in other sites 
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(lung, brain), Herpes simplex virus (with mucocutaneous ulcer > 1 
month, bronchitis, pneumonia), Kaposi’s sarcoma (in subjects <60 
years), Micobaterium avium or M. kansasii extrapulmonary, 
Pneumocystis jiroveci pneumonia, Progressive multifocal 
leukonecephalopathy, cerebral Toxoplasmosis. For the other AIDS 
conditions it is mandatory a laboratory confirmation: 
Coccidioidomycosis extrapulmonary, HIV encephalopathy, 
Histoplasmosis disseminated, Isosporiasis (chronic > 1 month), 
Kaposi’s sarcoma (with > 60 years), other lymphoma non Hodgkin, 
cervical cancer invasive, Mycobacterium tuberculosis pulmonary and 
extrapulmonary, pneumonia recurrent (≥ 2 episodes in 1 year) 
wasting syndrome and Salmonella bacteremia recurrent2.  
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HIV INFECTION THERAPY  
CLASS DRUGS REGIMEN AND HOW TO START WITH 
HAART  
The introduction of highly active antiretroviral therapy, HAART 
(or combined antiretroviral therapy cART), has modified the natural 
history of HIV determining the reduction of AIDS-deaths since 
199617, although the presence of mutation HIV-related and the onset 
of side effects drug-related, that compromise both adherence and 
efficacy18. There are more than 20 different drugs, belong to different 
classes, with a triple combination, essentially, to permit a virologic 
control19. Here the drug classes: reverse transcriptase inhibitor that 
includes both nucleosidic/nucleotidic reverse transcriptase (NRTIs) 
and non nucleosidic/nucleotidic reverse transcriptase (NNRTIs), 
integrase inhibitors (INIs), protease inhibitors (PIs), entry inhibitors 
(EIs) both fusion inhibitors and CCR5 antagonists. NRTIs are 
nucleosidic/nucleotidic like structures modified: thymidine related 
structures: zidovudine (AZT) and stavudine (d4T); guanosine related 
structures: abacavir (ABC); cytosine related structures: zalcitabine 
(ddC), lamivudine (3TC) and emtricitabine (FTC); finally adenosine 
related structures: didanosine (ddI) and tenofovir (both TDF and TAF). 
Normally, 2 NRTIs of different nucleosidic/nucleotidic structures 
work together as synergic effect, establishing the “backbone” of the 
therapy plus a third drug (from another drug class). NNRTIs 
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inhibitors that inhibit the reverse transcriptase with a directly 
connection to the enzyme (no competitive bind). They are: delavirdine 
(DLV), nevirapine (NVP), efavirenz (EFV), etravirine (ETR) and rilpivirine 
(RPV). Protease inhibitors are saquinavir (SQV), ritonavir (RTV), 
indinavir (IDV), nelfinavir (NFV),  amprenavir (APV), fosamprenavir 
(FPV), lopinavir (LPV), tipranavir (TPV), atazanavir (ATV) and darunavir 
(DRV); they determine the production of not infected virions; 
important historical class that modified the life expectancy of HIV 
living people20. Entry inhibitors are a small heterogenic class that 
includes enfuvirtide (T-20) and maraviroc (MVC): two drugs that 
cannot be used in the first line regimens as third drug class regimen. 
Finally the most recent and important class of integrase inhibitors 
that includes: raltegravir, (RAL), elvitegravir/cobicistat (EVG/cobi) 
and dolutegravir (DTG) stopping the integration of cDNA at the level 
of nucleus cell.  
The aims of HAART are: 
• reduction of morbidities and increase of life expectancy  
• improvement of the quality of life  
• recovery and/or maintenance of immune system functions  
• suppression of viral load  
• prevention of the transmission of HIV  
After the results from START study, all HIV patients have to start the 
therapy as soon as possible according the regional guidelines.21 An 
efficacy response to HAART includes a 16 weeks reduction, a CD8 T 
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cells reduction after 2 weeks, a slow increase of CD4 T cells number, 
a reduction of activated T cells phenotypes. Although the recent 
antiretroviral regimens, a portion of the patients around 20-30% 
doesn’t respond adequately to HAART; probably different factors can 
contribute to restrict the CD4 T cells recovery: nadir pre-HAART, an 
advanced age, a persistence detected viral load (often due to bad 
therapeutic compliance), the presence of microbial translocation and 
an immunologic unique background specific-individual. After the 
introduction of HAART, it is not possible to interrupt it due to a risk 
of a virological rebound and a CD4 T cell count decline23. According 
recent guidelines (DHHS, EACS, SIMIT), the INIs represent one of the 
most important antiretroviral class due a mix of positive factors: one 
of which the low level of toxicity; an interesting speed of viral load 
decay too (highest with INIs); finally formulation often with STR 
(single tablet regimen) for DTG and EVG/cobi, that is crucial for an 
efficient durability, to improve the quality of life (reducing pill burden) 
and to avoid virological failures (HIV-RNA >400 cp/ml after 24 weeks 
or >50 cp/ml after 48 weeks). According EACS guidelines 2017 in the 
first regimen we can enumerate many INIs + backbone combination 
and only one NNRTI based regimen and one PI based regimen: 
• DTG/ABC/3TC (with caution for people with cardiovascular 
risk) or DTG + TAF (or TDF)/FTC 
• EVG/cobi/TAF (or TDF)/FTC 
• RAL + TAF (or TDF)/FTC  
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• RPV/TAF( or TDF)/FTC (not for VL > 100.000 copies/ml) 
• DRV/cobi/FTC/TAF (or TDF/FTC) 
Unfortunately, the 10% of the patients have to change the first line 
regimen due to toxicity and/or virological failure and/or low 
therapeutic adherence23. No evidence of beneficial effect of a short 
term four drugs regimen for patients with highly viral load (mega-
HAART) with exception of virus with several resistance mutations at 
baseline; on the contrary, it is possible to switch to dual therapy in 
presence of toxicity confirmed during a triple regimen, although, until 
today, we don’t know if it is more beneficial the use of a dual therapy 
(especially the new dual therapy nuc-sparing as DTG/RPV) vs the 
classical triple therapy (especially containing TAF); probably future 
studies could solve this question. Other dual therapy include the 
association between a PI and 3TC (especially DRV/cobi (or rtv) + 3TC 
or ATV/cobi (or rtv) + 3TC); as well as the association 
RAL/DRVcobi(rtv) or RAL/ETR or ETR/DRV/cobi (or rtv); not 
recommended both ATV unbosted and RAL or RAL + 3TC regimens. 
PI-monotherapy regimen (only DRV based, drug with high genetic 
barrier) it is not recommended due to the best profile of DRV/cobi (or 
rtv) + 3TC. Alternative regimens include the use of the other 
backbone, ABC/3TC, in association to the other third molecules (with 
exception of DTG/ABC/3TC, first line regimen): indeed this backbone 
is not recommended for VL > 100.000 cp/ml; the use of other third 
drug as PIs (ATV/cobi) or NNRTIs (EFV); the use of the dual therapy 
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RAL/DRV (cobi or rtv); other combinations are optional or not 
recommended. The choice of the HAART has to consider many 
factors: the power of the molecules (EVG, DTG, RAL, EFV, DRV) and 
the power of the combinations; the virological decay speed 
(INIs>NNRTIs>PIs); the presence of mutations at baseline and the 
genetic barrier with or without a not perfect therapeutic compliance 
prevision (low genetic barrier: 3TC, FTC, NVP, EFV, DLV, RPV, T-20, 
PIs without RTV/cobi; intermediate genetic barrier: INIs as RAL and 
EVG/cobi, ETR, ddI, TDF, ABC; high genetic barrier: DTG, PIs with 
cobi/RTV, AZT, d4T; possible better immunologic outcome (MVC, not 
proved for INIs); allergy (cross reaction between sulfamidic molecules 
and DRV); drug-drug interactions (regimens with cobi or RTV), life-
style of the patient and its role for a good adherence (better STRs 
with/without no food assumption); CPE score in case of HIV 
encephalopathy (high CPE score for DTG, DRV, AZT, IDV, NVP). New 
drugs are bictegravir, a new INI DTG-like, as STR in combination with 
TAF/FTC, and a new NNRTI, doravirine, in a STR combination with 
TDF/3TC. Some studies are on-going to discover new formulation 
long-acting and new drugs for entry-inhibitors and the new class of 
maturation-inhibitors. 
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DRUG RESISTANCE  
HIV produces about 109-1010 virions/day; with vast genetic 
variability due to new mutations by reverse transcriptase (one 
mutation every 10.000 nucleotides that means one mutation every 
single cycle). In this scenario other factors can contribute to develop 
drug resistances: the use of drugs with low power, the therapeutic 
adherence and the pharmacocinetic interactions. Several studies 
showed the low number of mutations by virological failures during a 
PI-first regimen compared to NNRTI first regimen. In any case, NNRTI 
based regimens show a better profile because well tolerated: in this 
case, 3 molecules, with low genetic barrier, can maintain a durability 
(with a good therapeutic compliance) due to the difficult for HIV to 
create 3 mutations for the same regimen. INI based regimen seem to 
be promising molecules, especially DTG based regimens which was 
superior to DRV in Flamingo study22. It is mandatory to perform a 
resistance test before to start an HAART regimen, often showing a 
wild type, and especially in case of virological failure; indeed, it is 
important to note that in 10% of patients that starting HAART, there 
are mutations not detectable from plasma due to the presence of a 
wild type which has a high speed replication fitness. The first 
resistance test could detect NRTIs mutations, recalled TAMS,  with 
two different patterns: TAM1 (M41L, L210W, T215Y) and TAM2 
(D67N, K70R, T215F, K219Q/E) with a possible cross resistance to  
21 
 
ABC, ddI e TDF especially with TAM1 profile and in presence of other 
mutations: G333E/D, N348I, A360T, A371V e Q509L. In particular, 
the N348I is often associated both to AZT resistance and to NNRTI 
drugs as NVP and EFV. Other type of mutations for this class are: 
M184V, Q151M complex, K65R and L74V/I. With exception of ETR (a 
second generation NNRTI), all other NNRTI molecules are low genetic 
barrier molecules both first generation (DLV, EFV, NVP) and second 
generation (RPV). NNRTI mutations include: K103N/S, V106A/M, 
Y181C/I/V, Y188L/C/H e G190A/S/E. For ETR not all mutations 
are important: Y181I/V presents a high score in association to L100I, 
K101P, Y181C and M230L. The 103N doesn’t confer resistance to 
ETR, so it is possible to use ETR after EFV failure; unfortunately RPV 
has got a low resistance genetic barrier: K101P, Y181I/V, and 
especially E138K that invalidate the use of EFV and ETR too. Into PI 
class regimens, major mutations for third generation drugs (DRV and 
TPV) are: V11I, V32I, L33F, I74V, I50V, I54L/M, T74P, G73S, L76V, 
I84, L89V (V11I and L89V are DRV related).  For INIs, RAL related-
mutations show Q148H/K/R, N155H or Y143R/H/C. Association 
among Q148H and G140S determines resistance both RAL and EVG. 
For EVG there are: T66I, E92Q, S147G, Q148R/H/K and N155H. 
After this scenario of INIs resistances, it could be possible to remedy 
with the introduction of DTG-high dosage: 60% of success for multi-
experienced patients, until the presence of mutation 148 (crucial for 
DTG)19.
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DRUG TOXICITY HAART RELATED  
The management of HIV infection includes the monitoring of 
side effects drug-related. Lipodistrophy represents one of the most 
important side effect due to the use of old antiretroviral agents, as 
tymidine-related molecules and PI regimens23,24,34. Glucidic and 
lipidic alterations are common with PI, some NNRTI as EFV and 
backbone40; for example, insuline-resistance or diabetes with 
respectively 10% and 5% of incidence occur during PI based regimens 
treatment through the block of GLUT1 and GLUT425. All these 
conditions can determine the onset of metabolic syndrome and an 
increase in cardiovascular events, especially with ABC and PIs. Other 
important endocrinologic targets for antiretroviral agents are the bone 
metabolism with the onset of osteoporosis26,27 especially due to PIs28 
and some NRTIs (TDF), and thyroid function alterations that is 
correlated to d4T use29,30. At gut level it is important to enumerate 
different gastrointestinal disorders as dyspeptic syndrome, loss of 
appetite, diarrhoea, nausea, vomit, pyrosis, abdominal pain, 
meteorism and constipation31; often PI-related. A specific target is the 
liver, whose hepatotoxocity is related to NRTIs and PIs, with final 
result of liver steatosis32,36 or sever hepatitis with some NNRTI as 
NVP; finally, unique and particular is the increase of indirect 
bilirubin related to ATV administration33 (Gilbert syndrome-like). 
Central nervous system is altered during EFV administration34 with 
dizziness, insomnia, nightmares and depression; the latter recently 
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associated to DTG and RPV too. Peculiar is the mitochondrial toxicity 
NRTIs related that can determine lactic acidosis, hepatic steatotis, 
pancreatitis and peripheral polyneuropathy with myopathy35. Allergic 
reactions can occur with all drugs, especially NNRTIs class regimen 
with hypersensitivity reactions within 12 weeks36, from classical 
Steven-Johnson to hypersensitivity reaction ABC-related to HLA-B 
5701 aplotype. The kidney is another target often due to the action of 
IDV and TDF37,38,39, with nephrolithiasis or kidney failure and/or 
Fanconi syndrome due to tubular damage42. Rhabdomyolysis is 
peculiar for RAL whose appearance determines the suspension of the 
treatment.
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IMMUNOPAHOTEGENESIS AND ROLE OF IMMUNE-
ACTIVATION ON THE HIV INFECTIONS 
PATHOGENESIS 
HIV INFECTION IMMUNOPATHOGENESIS, T-CELLS 
ELEVATED TURNOVER AND IMMUNE-ACTIVATION 
MARKERS 
 
For every clinical phase previous described, HIV uses the 
immunologic cells to spread out through the different compartments. 
After the entry through mucosal sites, HIV infects the T cell 
lymphocytes, macrophages and dendritic cells stabilizing in its new 
reservoir, which includes spleen, lymph nodes and lymphoid tissues. 
The first contact involves the gp120-gp41 with CD4 receptor which is 
present in many different sub-types of immunologic cells as T cells, 
macrophages/monocytes and dendritic cells. The first contact 
permits the consecutive second contact between sp120 and one of the 
two most important chemokines co-receptors: CCR5 and CXCR4: this 
second contact is mandatory for HIV to infect the cells. There are HIV 
virus species specific for CCR5, recalled R5 or M-tropic (M from 
macrophage), on the contrary, other HIV species virus specific for 
CXCR4, recalled X4, are also T-tropic (from T cells tropic); finally 
there are HIV-species with tropism for both co-receptors: dual-tropic. 
M-tropic viruses express tropism for macrophages, monocytes and 
lymphocytes; on the contrary T-tropic viruses express tropism 
exclusively for T-cells. It is important to specify that dendritic cells 
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are infected from M-tropic, lymphocytes have both co-receptors with 
CD4+memory that are preferably infected from M5: its involvement 
determines a worse scenario due to both its activation for 
immunologic response versus the virus, and the chemotaxis effect by 
these cells to other lymphocytes, emphasizing the transmission4. 
CD4+ memory cells, strong target of HIV, are different from naive and 
effector cells: memory cells are CD45RO+ CD25+ CD62L+; on the 
contrary Naive cells are CD45RA+ CD62L+ CCR7+ and CD127+; 
finally effector memory are CD127+ CD44+ and variable expression of 
CD62L and CD45RO45,46,40. Feature of CD4+ memory is their 
dependence from naive CD4 cells, due to the higher levels of CD4+ 
apoptosis after activation compared to CD8+ turnover. Other 
distinctive aspect is the impossibility to convert an effector CD4+ cell 
to memory phenotype due to the lower expression of CCR7, that 
impedes the movement to lympho-nodal tissues41,45,46,47. After the 
entry of the virus, M-tropic virus infects immunologic cells through 
gut lamina propria, which is the most vast immunologic site of the 
body. The decay of immunity system at gut level occurs rapidly, 
without modification of plasma lymphocytes count, especially during 
the first 3 weeks51; successively, during years, there is a switch from 
M-tropic to T-tropic that determines the final stage of AIDS. Every 
day there is the production of 100*109 new virions in association to 
the death of 1-2*109 CD4 T-cells, with a loss of 50-100 cells/μl 
/year/plasma51. In this scenario it is important to note:  
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• Modifications of lymphonode architecture  
• Death of cells due to activation from other pathogenic triggers 
(other infections) or HIV its-self 
• Destruction of the precursors both direct infection either 
absence of cytokines 
• Infected cells fusion creating giant cells due to the action of X4-
tropic viruses through the contact between gp 120 by infected 
cells to CD4+ of not infected cells.  
• CD8+ T-cells activation targeted versus the complexes made 
between the bond of soluble gp120 and CD44.  
During the chronic phase the 30% of lympho-nodal CD4+ T cells 
count have viral RNA; on the contrary in the blood compartment the 
viral RNA tends to be zero during virologically suppressive HAART; 
moreover, other important different is the final viral target: memory 
cells at lympho-node level, naïve for blood compartment. In these 
conditions, the best reservoir is probably represented by lymphonode 
and, especially, innate immunity cells42. Douek et all described the 
presence of an altered and increase turnover T cells with a reduced 
life-time of all lymphocytes49 (see fig.4):  
- increase in production, but not in survival time, of CD4+ T cells 
count during HAART 
- reduction in CD4+ T cell, memory and naive, due to chronic 
activation 
- reduction of lympho-nodal dendritic cells and plasmacytoid cells 
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- high number of CD8+ T cells with an inversion CD4/CD8 ratio. 
Features of the HIV infections are either the CD4+ T cell count 
depletion or the elevated turnover T cells. The first feature creates the 
conditions to develop AIDS events, as quantitative damage; in any 
case, the second feature is peculiar for chronic infections and 
represents a qualitative damage. Indeed, the latter could be 
consequence of reactivation of other viruses (for instance EBV or 
CMV) or direct consequence by HIV replication that results in T-cells 
anergy and apoptosis.  Moreover, HIV+ presents higher expression of 
CD38+ and HLA-DR on CD4+ T cells (with a concomitant increase in 
Fas) and especially on CD8+ T cells compared to controls. Peculiar is 
the reduction of CD45RA+ CD62L+, Naive cells, both CD4+ and CD8+ 
T cells with a relative increase in memory activated CD45R0+ CD4+. 
CD38 is a further activation marker that correlates with short 
survival in absence of HAART43. Steven G Deeks et al44 have shown 
an inverse correlation between plasma-HIV-RNA and CD4+ cell count 
in naive patients; a positive correlation between CD8+ cells and viral 
load; finally a negative correlation between viral load and activation 
markers. Probably different components can explain the develop and 
the persistence of peripheral immune-activation during HIV infection 
(see fig.5) and its partial response to HAART. 
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Fig 4: from Douek et al. upper without HIV, below with HIV 
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Fig 5: possible causes of immune-activation 
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MICROBIAL TRANSLOCATION AND GUT INFLAMMATION 
DURING HIV INFECTION AND IMMUNERECOVERY HAART 
RELATED  
 
One of the most captivating hypotheses of immune activation, 
is the theory of microbial translocation, defined as the passage of 
bacterias or bacterial components, from the gut to extra-intestinal 
sites, such as plasma, linfonondes, spleen, liver. One kind of evidence 
that corroborates this hypothesis is the presence of positive 
correlation between the microbial translocation of ecological bacterial 
niches, especially some components, such as LPS, and immune-
activation. Indeed today we can consider it as a marker of microbial 
translocation. LPS is a common component of gram negative 
bacterias, that increases in course of sepsis. It constitutes the 40% of 
external cell wall and it circulates bind to LBP (protein binding LPS) 
and/or soluble CD14 (sCD14), a monocyte protein. There is a 
complex among LPS/LBP/sCD14 that binds the TLR4-MD2 receptor: 
a classical PRR (pathogen recognition receptor) that recognises 
PAMPs (pathogen associated molecular pattern), in this specific case 
the LPS. The subsequent signaling determines proliferation and 
immunologic activation with increase in cytokines45. Brenchley et al. 
have shown higher plasma LPS concentration in patients HIV+ with 
CD4+ T cell count below 200 and with AIDS diagnosis46. Merlini et al 
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have shown the presence of polymicrobic flora translocating into the 
peripheral blood of HIV+ patients with inadequate immune recovery 
during effective cART47. Recently, Tincati et all.48 have shown 
anatomical abnormalities that accompany gut injury during HIV 
infection that include the impairment of the intestinal junctional 
complex: reduced expression of cadherins, claudins, occludins 
especially in patients with no adequate immunerecovery; moreover, it 
was found an alteration of permeability measurers among between 
HIV+ and HIV- individuals as well as inflammatory markers with an 
increase in faecal calprotectin at gut level. Faecal calprotectin is 
produced by gut neutrophils and gut activated monocytes, as occurs 
in other gut inflammatory diseases, with the batteriostatic and 
micostatic function, above the normal cut off (> 50 g/g of feces). 
Regard to calprotectin there are two conditions: soluble and cell-
membrane-bound; the first is produced by neutrophils and 
monocytes after immunologic activation by LPS, IL-1 , C5a, IL-6 and 
TNF- ; the second works as adhesion component between cells and 
extracellular matrix. All these evidences permit to emphasize the 
relevance of the mucosal gastrointestinal tract as key factor to control 
comorbidities and improve the clinical outcome of HIV patients. 
Another complementary aspect is the presence of antibodies, IgM, IgG 
and IgA class, specific for the endotoxin core of LPS, recalled 
EndoCAb, that there are in all subject as natural immunologic 
response to bacterial fragments passage, and that are reduced in HIV 
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subjects compared to HIV negative controls49: the reduction of these 
antibodies, during elevated microbial translocation, occur because 
the ELISA test for EndoCAb measures the free part of the antibodies 
not bound to LPS, so, with a concomitant increase of LPS, there are 
more immunologic complexes and a subsequent reduction of free 
EndoCAbs. Hazenberg e al.50 have shown that the most important 
recovery occurs during the first 4 weeks after introduction of 
antiretroviral therapy, although without obtain the normal CD4+ and 
CD8+ cell count, even after years of HAART. Also, the introduction of 
HAART determines a reduction of immune activation with an increase 
in EndoCAb and a reduction in all other microbial translocation 
markers and immune-activation parameters, without a complete 
normalization51.
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FAECAL MICROBIOTA 
MICROBIOTA IN HEATLHY INDIVIDUALS  
The human microbial ecosystems comprises bacteria, archaea, 
eukaryotes and viruses which colonize different body habitats 
including the gut, skin, vagina, and respiratory tract. Several studies 
showed the central role of commensal bacterias at gut level for 
immunologic, metabolic and integrity functions52,53; indeed germ free 
animals have dramatic level of destruction of gut mucosal integrity 
and impairment of its immune system. At gut level the total number 
of prokaryotes located as ecological niches includes 14*1013/1014 
bacterias recalled microbiota, with an amount of genetic material of 
3*106, that is 100 times higher the value of the human genome 
(3*104), through 1000 bacterial species, more than 150 genera54, 
recalled microbiome; although the two terms are different, it is 
important to note that microbiota and microbiome are used 
interchangeably by scientific community. The vast majority of 
bacteria in the colon are strict anaerobes which are able to perform 
saccharolytic fermentation of non-digestible substrates from dietary 
fibres, making energy and nutrients for host and symbiont 
communities. Few divisions have been identified in the human gut: 
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, 
Verrucomicrobia and Fusobacteria. The human gastrointestinal 
microbiota is dominated by the first four main bacterial phyla whose 
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99% of species identified are mainly to the two first phyla, Firmicutes 
and Bacteroidetes, representing together 70% of the total 
microbiota55, with different distribution according the gastrointestinal 
tract (see fig. 6A) and with Bacteroides, Faecalibacterium and 
Bifidobacterium as the most abundant genera although in 
association to higher variable faecal relative abundance among 
individuals56 (see Fig. 6B). The human microbiota is individual 
specific and relatively stable during adult period but with strong 
differences according to the age from childhood (with higher 
Clostridium spp and Bifidobacteria spp.) to elderly age (increase in 
Firmicutes/Bacteroidetes ratio); moreover other important factors 
could influence the diversity of microbiota: both gender and sexual 
behaviours, the BMI (with different microbiota profile in obese 
individuals), the kind of diet, the geographic area and, of course, the 
presence of antibacterial agents or pre/probiotics. Other condition 
that could also modify the distribution of microbiota are the different 
gastrointestinal disorders as intestinal inflammatory diseases, 
metabolic diseases as diabetes, autoimmune disorders as celiac 
disease or other condition not present in healthy population57 (see 
Fig.7). The microbiome is essential for gut health through its 
metabolic function using the diet carbohydrates which are fermented 
to short chain fatty acids (SCFA) in the colon: acetate, propionate and 
butyrate. SCFAs are the major metabolic products of anaerobic 
fermentation, with total concentrations of 50–200 mM in the colon, 
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that can bind specific immunologic receptors and, subsequently, to 
be used as sources of energy, as regulators of gene expression for 
epithelia integrity and for immunologic interactions. If acetate is a 
fermentation product for most gut bacterias, the other two SCFA, 
propionate and butyrate, are considered healthy SCFAs, with a 
different subset of bacteria producers. Priopionate is metabolized 
through two pathways: the succinate and the propanediol pathways.  
The succinate pathway is found mainly in Bacteroidetes and in the 
Negativicutes class of Firmicutes (but also in some members of 
Ruminococcaceae); the propanediol pathways is used by 
Lachnospiraceae (Roseburia inulinivorans and Blautia species) and 
other few bacterial species. Butyrate is the final metabolic step from 
butyryl-CoA, which proceeds either via butyryl-CoA:acetate CoA-
transferase or via phosphotransbutyrylase and butyrate kinase. 
Butyrate-producing species are distributed among different taxa, with 
propionate-producing species, especially in the two predominant 
families of human colonic Firmicutes, Ruminococcaceae (essentially 
Faecalibacterium prausnitzii) and Lachnospiraceae (especially 
Eubacterium, Roseburia, Anaerostipes and Corpococcus genera) and 
in other Firmicutes families as Erysipelotrichaceae and 
Clostridiaceae58. 
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Fig.6A and 6B 
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Fig.7 
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ECOLOGICAL MEASUREMENTS: Α AND Β DIVERSITY 
To study the differences from human gut microbiome, it’s 
possible to use a NGS (next generation sequencing) technology where 
it is mandatory the DNA extraction followed by amplification and 
sequencing of ribosomial 16S DNA, a relatively short sequence highly 
conserved within a species, with high-throughput DNA sequencing; 
subsequently the identification through taxonomic alignment 
compared to reference sequences in database, with a similarity at 
least of 97% (today it is possible until 99%) for single taxa. After all 
this pipeline, often using a package of software (for example Qiime2), 
it will be possible to obtain all the OTUs (operational taxonomic unit) 
from phylum to species (phylum, class, order, family, genus, species), 
and in some cases the differentiation among ASVs (amplicon 
sequence variants) that allow to discriminate between two bacterias 
belong to the same species. An important aspect is linked to the 
portion of the r16SDNA selected to amplify: some authors amplified 
the hyper-variable V4 regions, instead of V3-V4 or other regions; it is 
important to specify that the choice of the r16SDNA region could 
determine a different ability to better distinguish species that belong 
to specific taxa instead of others. In any case, we can assume that 
the different methods are comparable although this bias59; on the 
contrary it is not possible to compare the features found in other 
biological materials as anal swab and/or gastrointestinal biopsies. 
The analyses of comparison of relative abundance for each taxonomic 
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level is a simple and initial step to analyse the differences among 
groups; anyway, given the great amount of bacterias and the 
difficulty in comparing these results, many authors prefer to evaluate 
the microbiota distribution using ecological diversity parameters, 
such as α and β diversity, that broaden the features found with 
relative abundance. The concept of “α and β diversity” was introduced 
in ecology by R.H. Whittaker: the former is the number of the species 
in a specific geographic community; the latter is the number of 
communities in a specific geographic area; finally, γ diversity is the 
product of α and β diversity. In humans, α diversity measures the 
level of diversity within individual samples, while β diversity 
measures the level of diversity (or dissimilarity) between samples60. 
Two important concepts are related to α diversity: richness and 
evenness. Richness is the number of different species represented in 
an ecological community, landscape or region. It is simply a count of 
species, and it does not take into account the  abundances of the 
species or their relative abundance distributions. On the contrary, 
evenness refers to how close in numbers each species in an 
environment is. There are different parameters to compare α 
diversity: according to observed parameter  it is possible to evaluate 
how many species there are, without capture the relatedness among 
species (a qualitative measure of  community richness); PD 
(phylogenetic diversity or Faith’s PD) determines how close the related 
species count are each other; so the latter is a measure of the level of 
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evolutionary diversity (measure of tree of life) and it indicates a 
qualitative measure of community richness that incorporates 
phylogenetic relationships between the features. Unfortunately both, 
observed and PD, don’t consider the distribution. Another richness 
method is Chao1:  
It emphasizes the importance of rare OTUs found in a sample: 
number of observed species add the ratio of the square of singletons 
(only saw one sample) divided by two times the number of 
doubletons61. Community diversity indices combine species richness 
and abundance into a single value of evenness. Gotelli et al. specified 
that communities that are numerically dominated by one or a few 
species exhibit low evenness while communities where abundance is 
distributed equally amongst species exhibit high evenness.  Two of 
the most widely used indices are the Shannon (or Shannon-Wiener) 
index (Shannon, 1948) and Simpson’s index (Simpson, 1949). 
Shannon index quantifies the entropy in strings of text:              
      
if practically all abundance is concentrated to one type, and the other 
types are very rare (even if there are many of them), Shannon entropy 
approaches zero; when there is only one type in the dataset, Shannon 
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entropy exactly equals zero. Because Shannon includes richness and 
abundance, it is often considered a diversity index instead of a 
richness or evenness index; according to other authors it is possible 
to simplify it as a quantitative measure of community richness; to 
solve this problem, some authors used the Shannon evenness index: 
this latter index presumes that the most equitable community could 
have equal number of OTUs (Shannon index divided Ln(OTUs) or 
Pielou’s evenness): becoming a measure of community evenness. 
Simpson index measures the degree of concentration when 
individuals are classified into types. The measure equals the 
probability that two entities taken at random from the dataset of 
interest represent different types, or the same type if we consider 
inverse Simpson: :  
Because every single index expresses different α diversity 
informations, it is possible to use all or some of these indexes62,63,64. 
Β diversity measures use the principle coordinates analysis, PCoA 
(any distance matric, not only Euclidean distance) through a non 
matrix multidimension scale (NMDS) where there are the two 
principle component analysis (PCA). The most used β diversity 
metrics are:  Jaccard distance: a qualitative measure of community 
dissimilarity; 
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Jaccard 
index measures the similarity between finite sample sets, and it is 
defined as the size of the intersection divided by the size of the union 
of the sample sets; on the contrary 1-Jaccard index is the Jaccard 
distance that is complementary to the Jaccard coefficient, so a 
dissimilarity measure. Bray-Curtis 
distance  
is a quantitative measure of community dissimilarity; where 2C{ij} is 
the sum of the lesser values for only those species in common 
between both sites. S{i}and S{j} are the total number of specimens 
counted at both sites: how much does one sample «undershoot» the 
other. Between 0 and 1, where 0 means the two sites have the same 
composition (that is they share all the species), and 1 means the two 
sites do not share any species. Both (Jaccard and Bray-Curtis) don’t 
consider the relatedness among species; so, after the inclusion of this 
information, it is possible to use the UniFrac distances where d= «0» 
that means identical community, 1 unrelated community, 0,5 related 
community. It measures “the percentage of observed branch lenght 
unique to either sample”; Unweighted unifrac only uses 
presence/absence, so emphasizes the minor bacterias, as a 
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qualitative measure of community dissimilarity that incorporates 
phylogenetic relationships between the features; Weithed unifrac 
considers count of relative abundances (it weights the branch lengths 
by the abundances of bacterias, so emphasizes the dominant 
bacterias), as a quantitative measure of community dissimilarity that 
incorporates phylogenetic relationships between the features. Β 
diversity could be represented by either PCoA and Ward's method 
criterion to generate the hierarchical clusters with the UniFrac 
taxonomic distance measures65. Finally, another way to measure the 
β diversity is the use of LEfSe analyses: LDA Effect Size (LEfSe)66 is 
an algorithm for high-dimensional biomarker discovery and 
explanation that can identify taxonomic groups characterizing the 
differences between two or more biological conditions. LEfSe identifies 
features that are statistically different among biological classes; 
subsequently, performs additional tests to assess whether these 
differences are consistent with respect to expected biological 
behaviour. The linear discriminant analysis effect size often uses a 
threshold of 2.0 for the logarithmic LDA score for discriminative 
features in addition to the strategy for multi-class analysis set to ‘all-
against-all’. LEfSe cladograms, compared to plots, represents the 
differences between two groups including the taxonomic informations 
(see Fig 8). 
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Fig 8 
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MICROBIAL DYSBIOSIS IN HIV INFECTION  
In the course of chronic HIV infection the GALT, the vastest 
immunologic compartment located at gut level, shows a dramatic 
deterioration, that comprises substantial loss of mucosal T-cells, 
disruption of intercellular tight junctions, pro-inflammatory infiltrate. 
An important alteration described in HIV-related GALT damage is 
dysbiosis with disruption of the residents ecological niches. Dysbiosis 
represents a change in the numbers of microbes and/or a change in 
the diversity of the microbiota due to specific diseases. A clear 
definition of dysbiosis is difficult because there is not agreement 
about the term of eubiosis due to intra-individual differences among 
distinct body sites and inter-individual variation among healthy 
individuals67,68. Some authors suggested an unbalance of microbiota 
with an increase in pathogenic bacteria (Pseudomonas aeruginosa e 
Candida albicans) and a decrease in other healthy genera 
(Biﬁdobacteriaceae e Lactobacilli) compared to controls69,70; it is 
important to note that before the introduction of NGS, all the 
previous works used the qPCR to detect specific taxa. After 
introduction of NGS, it was possible to detect alterations in 
composition and degree diversity, whose grade is difficult to 
evaluate71, with alterations of links between resident bacterias and 
immunity system, promoting gut and systemic inflammation with a 
possible association to tryptophan metabolism72. Lozupone at al. in 
2013 described a cluster separation with PCoA according Unifrac, 
46 
 
from faecal samples, between chronic naïve HIV subjects and controls 
with higher α diversity indexes (Shannon and PD)73. As relative 
abundance abundances of Prevotellaceae, Erysipelotrichaceae, 
Veillonellaceae families and Clostridium cluster XIII and Desulfovibrio 
genera compared controls; on the contrary HIV negative subjects 
showed increase in Bacteroidaceae, Rikenellaceae and 
Porphyromonadaceae. After this crucial study, new topics were 
described: the unbalance in Bacteroidetes phylum (Prevotella-
rich/Bacteroides-poor); an increase in α diversity instead of decrease, 
as occurs in other disease model; the effect of HAART; the impact of 
the diet or other factors that could justify these results. Indeed the 
Prevotella-rich microbiota resembles what described in healthy 
individuals in agrarian cultures of Malawi and Venezuela and 
associated to carbohydrate-rich, protein- and fat-poor diets. An 
evidence that an altered profile of Bacteroidetes phylum could play a 
pathogenetic role was suggested by other authors74,75 confirming  this 
unbalance at mucosal level (with an interesting decrease in 
Firmicutes and increase in Proteobacteria phylum, the latter not 
confirmed from faecal samples), that was associated with increased 
activated colonic T cells and myeloid DCs, in untreated79 patients. 
Similar findings were reported in treated patients80 with a reduced α 
diversity in both studies. Moreover, PCoA showed a microbiota 
associated with increased mucosal cellular immune activation, 
microbial translocation and blood T cell activation79. In a first review, 
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it was postulated a possible pathogenic role of Prevotella-richness 
community due to its association to an increased prevalence of 
cardiovascular disease and/or atherosclerosis, probably through the 
TMAO pathway and other species as Desulfovibrio, which is 
increased in HIV infection74. An important contribute was added by 
Noguera-Julian et al.76 that emphasized the important to control for 
sexual behaviour: MSM (men sex men) had an higher α diversity 
compared to other HIV+ epidemiological groups; moreover, within the 
MSM group, HIV was associated with reduced α diversity. This 
discovery can clarify why many authors have found contrasting data 
from different cohorts77.  
Few studies have thus far have investigated the impact of 
different antiretroviral agents78,79 or the impact of the introduction of 
HAART with a longitudinal design80.  
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BACKGROUND 
In the recent years, HIV-infected individuals have been reported 
to harbor a distinct gut microbiome (Zilberman-Schapira G et al, 
BMC Med 2016; 14:83; Lozupone CA et al, Cell Host Microbe 2013; 
14:329-339; McHardy IH et al, Microbiome 2013; 1:26; Mutlu EA et 
al, PLoS Pathog 2014; 10:e1003829), that have been associated to 
HIV infection itself, antiretroviral treatment, sexual orientation 
(Noguera-Julian M et al, EBioMedicine 2016; 5:135-146; Lozupone 
CA et al, Gut Microbes 2014; 5:562-570; Yu G et al, AIDS 2014; 
28:753-760 18, 61, 62+klatt science). Gut microbiome involvement in 
HIV transmission and pathogenesis is increasingly being recognized 
(Dillon SM et al, AIDS 2016; 30:2737-2751; Gootenberg DB et al, 
Curr Opin Inf Dis 2017; 30:31-43; Williams B et al, AIDS Res Hum 
Retroviruses 2016; 32:935-941; Vujkovic-Cvijiin I et al, Sci Transl 
Med 2013; 5:193ra91; Nowak P et al, AIDS 2015; 29:2409-2418), yet 
the findings and interpretation of the results diverge significantly 
among studies (Li SX et al, Clin Phramacol Ther 2016; 99:600-611), 
due to differences in cohort size, sampling, lack of adjustment for 
confounding factors, such as sexual practice and diet (Noguera-
Julian M et al, EBioMedicine 2016; 5:135-146; Shanahan F et al, Gut 
2017; 66:1709-1717).  
 
50 
 
Among the most consistent alterations described in untreated HIV, 
dramatic subversion of the Bacteroidetes phylum with an unbalanced 
Prevotella/Bacteroides pendulum, and the Proteobacteria phylum 
with enrichment in Enterobacteriaceae. Indeed, several sets of 
evidence have been provided to link IA and microbioma. In untreated 
HIV, several authors have described important alterations in enteric 
microbiota, particularly in phyla such as Proteobacteria, 
Bacteroidetes and Firmicutes with a shift toward a Bacteroides-
poor/Prevotella-rich profile and an enrichment in Enterobacteriaceae, 
a Gram-negative family of the phylum Proteobacteria, known to be 
involved in microbial translocation (Klase Z et al, Mucosal Immunol 
2015; 8:1009-1020), in turn contributing to residual immune 
activation (Klase Z et al, Mucosal Immunol 2015; 8:1009-1020; Dillon 
SM et al, Mucosal Immunol 2014; 7:983-994; Tincati C et al, AIDS 
Res Ther 2016; 13:19; Zevin AS et al, Curr Opin HIV AIDS 2016; 
11:182-190).   
Both cross-sectional and longitudinal studies have shown a limited 
effect of suppressive cART in restoring gut microbiome (Pinto-Cardoso 
S et al, Curr Opin HIV AIDS 2018; 13:53-60; Deusch S et al, AIDS 
2018; 32:1229-1237; Ji Y et al, Emerging Microbes & Infections 
2018; 7:113; McHardy IH et al, Microbiome 2013; 
1:26)80,68,81,78,79,72,82. Indeed, despite cART-treated HIV+ patients 
showed a gut microbiota composition different from the viraemic 
individuals, they also display a community structure distinct from 
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HIV- healthy subjects (McHardy IH et al, Microbiome 2013; 1:26; 
Lozupone CA et al, Cell Host Microbe 2013; 14(3):329-39; Nowak P et 
al, AIDS 2015; 29:2409-18. Taken together, data to link IA and gut 
microbiome and persistent alteration in cART, would suggest that gut 
microbiota alterations could contribute to the pathogenesis of 
residual disease that persist during suppressive antiretroviral 
therapy. Antiretroviral compounds could themselves further promote 
dysbiosis (Shilaih et al, Antiv Ther 2018; 23(1):93-94; Li SX et al, Clin 
Pharmacol Ther 2016; 99:600–611), and different cART regimens 
differentially impact the gut microbiome, markers of microbial 
translocation, inflammation/immune activation and the gut epithelial 
barrier damage, with cART-experienced individuals on protease 
inhibitors being worse off (Nowak P et al, AIDS 2015; 29:2409-2418; 
Pinto-Cardoso S et al, Sci Rep 2017; 7:43741; Villanueva-Millan MJ 
et al, J Int AIDS Soc 2017; 20:1-13).  
An exciting challenge that has been somehow neglected so far is the 
understanding of the contribution of the “circulating microbiota” to 
HIV-associated co-morbidities and its association with microbial 
translocation during effective cART. We have previously shown the 
presence of polymicrobic flora translocating into the peripheral blood 
of HIV+ patients with inadequate immune recovery during effective 
cART47, leading to wonder whether a diverse microbial composition 
into the blood might simply reflect the changes into the gut or might 
take actively part to the pathogenesis of HIV infection. Interestingly, 
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recent studies have demonstrated a role of blood microbiota in the 
onset of diabetes and athero-thrombotic disease in the general 
population83,84, possibly confirming a role of blood dysbiosis in non-
AIDS related co-morbidities. Despite the importance of the gut 
microbiome in HIV infection has been widely recognized, little is 
known on how HIV-related dysbiosis is associated with microbial 
translocation (MT) and gut damage and how long-term cART fits 
within this complex scenario. Thus, we decided to explore (i) the long-
term effects of cART on markers of gut damage/MT and gut/blood 
microbiota composition, with a focus on the role exerted by different 
drug classes and (ii) the possible associations between gut dysbiosis 
and peripheral inflammation/immune activation, microbial 
translocation and intestinal permeability. 
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MATERIALS AND METHODS 
STUDY POPULATION  
HIV-positive patients were consecutively enrolled at the Clinic 
of Infectious Diseases, Dept of Health Sciences, University of Milan - 
ASST Santi Paolo e Carlo, Milan, after providing written, informed 
consent in accordance with the Declaration of Helsinki. The 
Institutional Review Board at the ASST Santi Paolo e Carlo 
specifically approved the study. Inclusion criteria were: age >18 and 
naïve to cART with any CD4+ count and plasma HIV-RNA. The 
patients who were enrolled were from the same geographic area of 
Milan (North of Italy); individuals with signs/symptoms of 
gastrointestinal diseases were excluded. HIV+ patients underwent 
blood and faecal sampling prior to cART (T0) and after 12 (T12) or 24 
(T24) months of therapy. We also enrolled HIV-negative healthy 
subjects as controls. 
 
T-CELLS IMMUNEPHENOTYPES 
Lymphocyte surface phenotypes were evaluated by flow 
cytometry on fresh peripheral blood (FACSCanto II; BD Italy). We 
evaluated activation (CD45R0/CD38), naive (CD45RA) and memory 
(CD45R0) subsets and IL-7 receptor (CD127) on CD4 and CD8 T-
cells. Samples were stained with the following fluorochrome-labeled 
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antibodies: L/D V500, CD4 PE-Cy7, CD8 PerCPCy5.5, CD38-FITC, 
CD45R0-PE, CD45RA-FITC, CD127-PE (BD Bioscience).  
The following combinations were used: LD/CD8/CD38/CD45R0, 
LD/CD8/CD4/CD127 and LD/CD4/CD8/CD45RA/CD45R0. 
FACSDiva 6.1.3 software was used to analyze data. 
 
MICROBIAL TRANSLOCATION MARKERS 
Plasma sCD14 and Endotoxin Core Antibodies (EndoCab) were 
measured by ELISA (R&D systems), in accordance with the 
manufacturer’s instructions. Samples were diluted 1000X and 200X 
respectively. The total amount of 16S rDNA present in the samples 
was measured by qPCR in triplicate and normalized using a plasmid-
based standard scale (Vaiomer SAS, Labége, France).  
 
URINARY LACTULOSE-MANNITOL FRACTIONAL 
EXCRETION RATIO (LAC/MAN) AND INTESTINAL FATTY 
ACID BINDING PROTEIN (I-FABP) 
Participants were asked to fast the night before and to collect 
morning urine before drinking a sugar probe solution containing 5g 
lactulose and 2g mannitol. Urine was collected for 5 hours following 
administration of the double sugar solution and participants did not 
eat or drink (with the exception of water) until the end of the 5-hour 
collection. The total volume of urine was recorded and a 30mL aliquot 
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of chlorhexidine-preserved (0.236 mg/mL of urine; Sigma Chemical, 
St Louis, MO, USA) was frozen and stored for High Performance 
Liquid Chromatography analysis of lactulose and mannitol (Dionex 
MA-1 ion exchange column with pulsed amperometric detection on a 
Dionex Ion Chromatograph 3000, Thermo Scientific, Sunnyvale, CA). 
The ratio of lactulose and mannitol excretion (LAC/MAN) was 
assessed. Normal values were considered <0.0585,86. 
Intestinal Fatty Acid Binding Protein (I-FABP) was assessed by ELISA 
(Hycult Biotech), according to manufacturer’s instruction. 
 
FAECAL CALPROTECTIN LEVEL  
Calprotectin concentrations were measured by use of a 
commercial ELISA kit (Immundiagnostik, Bensheim, Germany), 
according to the manufacturer’s instruction. Briefly, two 100-mg 
samples of feces from a single stool sample from each participant 
were assayed, and the mean of the two measurements was recorded. 
 
GUT PERSISTENCE SCORE 
 A gut persistence score was calculated for all drug regimens. 
Briefly, given the known % of bioavailability for every single cART 
molecule, the % of RA-dose was arrived at for unchanged drug in 
feces, converted to a score between 1 (low persistence score) and 4 
(high persistence score). This way, a gut persistence score cART 
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regimen was calculated as the total of the values determined for the 
single component of the triple regimens.    
 
METAGENOMIC SEQUENCING OF BLOOD AND FAECAL 
SAMPLES  
Fresh stool samples and plasma were collected from each subject, 
frozen immediately and stored until processing at −80 °C. Total DNA 
was extracted as previously described87. The V3-V4 hypervariable 
regions of the 16S rDNA were amplified and quantified by qPCR, 
sequenced with MiSeq technology, and clustered into operational 
taxonomic units (OTUs) before taxonomic assignment as 
described87,88,89. The targeted metagenomic sequences from faecal 
and plasma microbiota were analyzed using the bioinformatics 
pipeline established by Vaiomer SAS from the FROGS guidelines. For 
bioinformatics pipelines FROGS v1.3.0 and PhyloSeq v1.14.0 were 
used. Briefly, after demultiplexing of the barcoded Illumina paired 
reads, single read sequences were cleaned and paired for each sample 
independently into longer fragments. After quality-filtering and 
alignment against a 16S reference database, a clustering into OTU 
(Operational Taxonomic Unit) with a 97% identity threshold and a 
taxonomic assignment were performed in order to determine 
community profiles.  The list of possible species for each unique 
sequence was further investigated using the BLASTN program from 
NCBI Blast against the NCBI 16S Microbial database. Only the 
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BLASTN hits covering the full query sequence length with an overall 
sequence identity of 97% or more were considered as possible 
species. Specifically, through FROGS v1.3.0 amplicons with these 
parameters were removed: with a length < 350 nt or a length > 480 
nt; without the two PCR primers (10% of mismatches were 
authorized); with at least one ambiguous nucleotides (‘N’). OTU 
identified as chimera (with vsearch v1.9.5) in all samples in which 
they were present were removed, as well as OTU with an abundance 
lower than 0.005% of the whole dataset abundance or with a strong 
similarity (coverage and identity >= 80%) with the phiX (library used 
as a control for Illumina sequencing runs). With regard to the 
clustering process: it was produced in two passes of the swarm 
algorithm v2.1.6. The first pass was a clustering with an aggregation 
distance equal to 1. The second pass was a clustering with an 
aggregation distance equal to 3. With regard to the taxonomic 
assignment: it was produced by Blast+ v2.2.30+ with the databank 
RDP v11.4 and filtered to ignore "unknown" taxa from the RDP 
database Finally, through the package PhyloSeq v1.14.0 it was 
possible to use a set of classes and tools to facilitate the import, 
storage, analysis, and graphical display of microbiome census data, 
after the exclusion all samples with less than 5000 sequences from 
FROGS processing for statistical analyses.  The DNA extracted from 
plasma for sequencing was evaluated by 16S qPCR. The total 16S 
rDNA found in the samples was measured by qPCR in triplicate and 
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normalized using a plasmid-based standard scale. The construction 
of a standard curves allows for a proper quantification of 16S rDNA 
gene copy in the sample, but also enables the determination of the 
efficiency, linear dynamic range, and reproducibility of the qPCR 
assay. In these experiments, the efficiency calculated from the 
standard curve was required to be between 80-120%, and the R2 of 
the standard curve greater than 0.980. Melting curve analysis was 
used for the assessment of heat induced dissociation-characteristics 
for double-stranded DNA to determine the specificity of the target 
PCR amplicons, including identification of the presence of non-
specific products and primer-dimers. This property was valuable 
because the presence of secondary non-specific products and primer-
dimers could affect the accuracy of the qPCR assay. The specificity of 
all qPCR products was assessed by the systematic analysis of the 
post-PCR dissociation curve performed between 60°C to 95°C. 
 
BIOINFORMATIC ANALYSES 
Reads obtained from the MiSeq sequencing system have been 
processed using Vaiomer SAS bioinformatics pipeline. Based on the 
results, graphical representations were made of the relative 
proportion taxa for each taxonomic level (phylum, class, order, 
family, genus, and species) present in individual study samples. Taxa 
are identified by name in the plot for abundance >1%. Taxa are 
merged into the “Other” category only if it exists in any sample with 
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abundance greater than 0.01%. Taxa are merged into the “Multi-
affiliation” category when they can correspond to two or more 
different taxa.  Α diversity (α-diversity) represents the mean of species 
diversity per sample in each group/class. Diversity analysis is 
presented for 1) observed, 2) Chao1, 3) Shannon, 4) Simpson, and 5) 
inverse Simpson. Principal Coordinate Analysis (PCoA) was performed 
for comparison of sample groups/class based on four methodologies 
for β-diversity: 1) Bray-Curtis, 2) Jaccard, 3) Unifrac, and 4) Weighted 
Unifrac. Finally, the output matrix containing the relative abundance 
of OTUs per sample was processed with the linear discriminant 
analysis effect size (LEfSe) algorithm66 using an α cut-off of 0.05 and 
an effect size cut-off of 2.0. The functional metagenome has been 
predicted using PICRUSt v1.1.190 as follow: the OTU representative 
sequences were used to pick OTUs against the GreenGenes reference 
tree (May 18, 2012 database) at 97% identity in order to convert our 
initial OTU abundance table into PICRUSt-ready OTU abundance 
table. The metagenome was predicted for each sample and the related 
pathways were retrieved from the Kyoto encyclopedia of genes and 
genomes (KEGG) pathways database and formatted for STAMP 
analysis. 
 
STATISTICAL ANALYSIS 
Continuous variables were expressed as median and 
interquartile range (IQR), whereas categorical variables were 
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expressed as absolute numbers and percentages. The different 
groups of patients and the different time points were compared using 
Fisher’s exact test, Mann-Whitney, Kruskal-Wallis or Friedman 
paired test as appropriate and the correlations among variables were 
tested by Spearman Rank correlation. P values <0.05 were considered 
statistically significant. Data were analyzed with GraphPad 5 Prism 
(GraphPad-Software).
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RESULTS 
STUDY POPULATION 
We consecutively enrolled 138 HIV-infected patients fulfilling 
the inclusion criteria. Table 1 shows the main characteristics of the 
study population. At baseline, 66/138 (48%) started a NNRTI-based 
regimen, 55/138 (40%) a PI-based regimen, 8/138 (6%) an INSTI-
based regimen and the remaining 9/138 (6%) started with mixed 
regimens. Following 12 and 24 months of suppressive cART, we 
observed viro-immunological improvements (Tab.1, coupled with 
decreased T-cell activation, redistribution of memory and naïve T-cell 
subsets (Fig.2 and Fig.2bis), increased I-FABP (p<0.0001) and 
EndoCAb (p<0.0001), yet stable sCD14 levels (Fig.3). The cohort 
diagram in Fig.1 illustrates the assignment of peripheral blood, urine, 
and stool samples to each analytical method. 
 
VIRO-IMMUNOLOGIC PARAMETERS, MICROBIAL 
TRANSLOCATION (MT), INTESTINAL DAMAGE AND 
INFLAMMATION MARKERS IN A SUB-GROUP OF 41 HIV+ 
PATIENTS STARTING A FIRST CART REGIMEN  
In an unselected sub-group of 41-infected patients who 
accepted and completed the longitudinal faecal collection (Table 2), 
we investigated blood/gut microbiota composition following the first 
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two years of cART and we compared these data to 15 HIV-uninfected 
healthy controls. Compared to HIV-negative healthy controls, HIV+ 
patients were younger (p=0.0017), with a higher proportion of MSM 
(p=0.039). In line with what observed in the entire cohort, two years 
of cART resulted in viro-immunological recovery, significant decrease 
of activated CD8 T-cells and a redistribution of memory and naïve T-
cells (Table 3). We next assessed circulating markers of gut damage 
and permeability, and microbial translocation (Figure 4). Upon cART 
introduction, we observed stable16S rDNA (Figure 4a), and sCD14 
levels (Figure 4b), along with a rise in EndoCAb (p=0.0001; Figure 4c) 
and I-FABP plasma levels (p=0.039; Figure 4d). Interestingly, while 
faecal calprotectin was stable over time (Figure 4e), it significantly 
decreased in those HIV+ patients with baseline calprotectin values 
above the range of normality (i.e. >50µg/g) (p=0.018; Figure 4f). 
Likewise, despite stable LAC/MAN ratio in the whole cohort (Figure 
4g), HIV+ patients starting cART with LAC/MAN ratio greater than 
0.05 displayed a significant reduction at T12 (p=0.031; Figure 4h). 
 
FAECAL BACTERIAL COMPOSITION AMONG HIV-
INFECTED PATIENTS AND HIV-INDIVIDUALS  
We first assessed the faecal α and β diversity, as well as the 
bacteria relative abundance between HIV+ and HIV- healthy controls. 
The α diversity richness indexes, but not the evenness indexes, were 
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higher in HIV+ patients, compared to the control group (observed: 
p=0.029; Chao1: p=0.011; Shannon p=0.184; Simpson p=0.303; 
Figure 5a). Following the linear discriminant analysis (LDA) effect size 
(LEfSe) with LDA score>2 as the cut-off, we found that compared to 
controls, HIV+ displayed higher Actinomycetaceae (p=0.01), 
Prevotellaceae (p=0.003), Lactobacillaceae (p=0.003), Peptococcaceae 
(p<0.0001), Succinivibrionaceae (p<0.0001) and Fusobacteriaceae 
(p=0.01) and lower Bacteroidaceae (p<0.0001), Ruminococcaceae 
(p=0.066) and Rikenellaceae (p<0.0001) (Figure 5b). These differences 
were confirmed by the subsequent analysis of the diverse taxonomic 
levels (phylum, class, order, family, genus and species). In particular, 
while we did not find major differences at the phylum level, we 
observed significant modification within the lower taxonomic levels, 
such as families and genera (Figure 7). Given that some authors have 
reported sexual behaviour, particularly men who have sex with men 
(MSM), as a driving factor of large microbiome differences76, we 
performed a sensitivity analysis in 28 MSM vs 13 heterosexuals in 
HIV+ at each time point. Interestingly, with regard to alpha diversity 
comparison, in HIV+ group we were not able to detect the same 
profound alteration of gut microbiota composition when we compared 
HIV-infected individuals MSM to HIV-infected individuals 
heterosexuals (that include MSW, female sex and 1 IDU patient)  
(fig.6). On the contrary, with regard to faecal relative abundance 
sensitivity analysis performed at taxa family for the 11 families 
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altered: we confirmed a strong sexual behaviour influence between 
MSM HIV+ individuals compared to heterosexuals HIV+ individuals 
(fig. 8a) with the typical Prevotellaceae-rich/Bacteroidaceae-poor 
unbalance; although, interestingly, we could detect many differences 
between  HIV+ heterosexuals and HIV- heterosexual subjects (fig. 8b). 
These unique microbial changes in HIV+ subjects lead us to 
hypothesize diverse metagenomic functions. To answer this question, 
we used the bioinformatics tool PICRUSt 
(http://picrust.github.io/picrust), that revealed similar predicted 
functional metagenomic pathways between the two groups (data not 
shown). 
 
EFFECT OF 24 MONTHS OF DIVERSE CART REGIMENS 
ON FAECAL BATERIA COMPOSITION  
Having shown a marked dysbiosis in HIV-infected patients, we 
next asked whether diverse cART regimens might result in 
modifications of gut microbiota composition. To address this 
question, we first analysed the impact of cART regimens overall, then 
we stratified our cohort according to the 3rd drug, i.e. NNRTI, PI or 
INSTI. The initiation of antiretroviral therapy did not lead to 
substantial modifications of richness and evenness parameters, with 
HIV+ patients maintaining significantly higher α diversity compared 
to healthy controls at T24 (observed: p=0.015 Chao1: p=0.002, Figure 
9a). Similarly, the LEfSe analysis showed a modest variation in gut 
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bacterial composition following 24 months of cART, with HIV+ 
patients still displaying higher Prevotellaceae, Lactobacillaceae, 
Peptococcaceae, Succivibrionaceae and Veillonellaceae but lower 
Bifidobacteriaceae, Bacteroidaceae, Rikenellaceae and 
Ruminococcaceae, as compared to HIV negative individuals (Figure 
9b). In line with the above-mentioned results, the principal 
coordinate analyses based on β-diversity results (Jaccard and 
Unweighted Unifrac indexes) revealed a tendency of HIV+ gut 
microbiome to cluster separately from HIV- healthy controls, 
irrespective of cART initiation (Figure 9c). Following cART, the relative 
abundance analysis revealed a significant increase in Veillonellaceae 
(p=0.004; Figure 10a) and a trend towards higher Desulfovibrionaceae 
(p=0.092; Figure 10b), coupled with a parallel decrease in 
Lactobacillaceae (p=0.020; Figure 10c), Coriobacteriaceae (p=0.004; 
Figure 10d) and Peptococcaceae (p=0.027; Figure 10e). Furthermore, 
at genus level we observed an increase in Allisonella (p=0.004; Figure 
10f), and Desulfovibrio (p=0.037; Figure 10g), with a significant 
decrease in Lactobacillus (p=0.020; Figure 10h), Eggerthella (p=0.049; 
Figure 10i) and Peptococcus (p=0.027; Figure 10j). Interestingly, this 
persistent dysbiosis was associated with the continuous mucosal 
damage, despite cART introduction. Indeed, the levels of the direct 
marker of intestinal damage (I-FABP) were positively correlated with 
Veillonellaceae both at T12 (r2=0.197; p=0.030;) and T24 (r2=0.156; 
p=0.017). Interestingly enough, when we stratified patients according 
66 
 
to cART regimens, we found that only NNRTI-based therapy 
significantly reduced richness (observed: p=0.038; Chao1: p=0.006; 
Figure 11a-b), but not evenness indexes (Figure 11c-d) over time. 
Furthermore, the relative abundance analyses showed a different 
profile at both family and genus levels, with NNRTI-based regimens 
significantly reducing the families of Coriobacteriaceae, 
Peptococcaceae and increasing the Veillonellaceae family (Figure 12a-
c). On the opposite, INSTI-based regimens resulted in decreased 
Peptococcaceae and increased Veillonellaceae families, as well as in 
higher Allisonella genus (Figure 12d-f). No major effects following PI-
based regimens were detected. The changes in gut dysbiosis 
according to diverse cART regimens, was accompanied by stable 
predicted metagenomics predictions (data not shown). With regard to 
our “gut persistence score” for each antiretroviral drug, based on the 
drug bioavailability and the proportion of unchanged drug in feces 
(courtesy of Dr. Calcagno A., University of Turin, Italy), we wanted to 
test the hypothesis of an indirect effect of cART on faecal microbial 
composition. We found that the gut persistence score was similar 
between PI-, NNRTI- and INSTI-based regimens over time (Figure 13a-
b). Furthermore, the gut persistence score did not associate with the 
faecal bacteria composition (data not shown). 
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BACTERIA Α AND Β DIVERSITY AND RELATIVE 
ABUNDANCE ANALYSES IN PLASMA  
Given the presence of microbial bioproducts within the plasma 
compartment of HIV-infected individuals despite cART 
introduction47,70,91, we also explored the composition of the 
translocating microbiota. The composition of blood microbiota was 
very different from the one observed within the faecal samples, with 
significantly higher relative abundance of bacteria belonging to the 
Actinobacteria and Proteobacteria phyla (Figure 14a-b), and lower 
bacteria belonging to the Firmicutes and Bacteroidetes phyla (Figure 
14c-d ). Focusing on blood composition alone, while richness 
parameters (observed and Chao1) did not highlight differences in 
bacteria composition (Figure 15a-b), evenness parameters (Shannon 
and Simpson) showed reduced α diversity in HIV+ vs healthy controls 
(p=0.02, p=0.009, respectively; Figure 15c-d). Β diversity analysis 
revealed no differences in plasma bacteria composition following the 
principal coordinate analysis (Figure 15e-f). We only found a higher 
Sphingobacteriales (p<0.0001), yet lower Chitinophagaceae (p=0.001), 
Cytophagales (p<0.0001) Sphingomonadales (p=0.01) and 
Enterobacteriales (p=0.029) in HIV-infected individuals compared to 
healthy controls (Figure 15g). In line with what observed in the feces, 
cART introduction modified the bacteria composition only partially, 
with slight variations of Sphingomonadaceae (p=0.04) 
Staphylococcaceae (p=0.01) and Pseudomonadaceae (p=0.031) 
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families (Figure 15h). With regard to a possible associations between 
these plasma taxa and microbial translocation markers, at baseline a 
weak positive correlation between EndoCab and Cytophagales 
(r=0.034,p=0.03) and a weak negative trend between 
Sphingomonadales and 16SDNA (r=-0.29, p=0.06) were found; on the 
contrary, no correlations between microbial translocation markers 
and the plasma taxa altered after cART introduction were found (data 
not shown). A similar trend was observed according to the diverse 
drug classes. Finally, in order to better investigate the role of cART in 
modifying bacteria composition, we also explored the faeces to 
plasma ratio of the different bacteria taxa, failing to find any 
modification of this ratio after 12 and 24 months of virologically 
suppressive cART  (data not shown). 
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DISCUSSION  
It is now widely accepted that, aside from the direct effect on 
gastrointestinal mucosal immunity, HIV infection is characterized by 
gut microbiome compositional and functional changes, not fully 
reverted by cART80,68,81,69,92,74,93,77,94,95,96. However, the causal 
relationship between altered intestinal microbiota composition, gut 
damage and cART is still an open question that needs to be answered 
in order to improve microbiome-targeted therapies. We hereby 
describe that 24 months of viro-immunological effective cART, while 
able to substantially reduce immune activation in the periphery, 
rescuing circulating T-cell immunephenotypes, still fail to fully 
restore gut health. In particular, our finding of a significant rise in 
plasma I-FABP levels suggest an enduring enterocyte damage despite 
24 months of cART, expanding on previous data by Chevalier et al. 
that show rising I-FABP in a cohort of acutely treated HIV+ patients 
(Chevalier et al. Plospath 2013), in all suggesting that even the 
promptest and long-term cART does not prevent gut mucosal 
damage. Alongside persistent mucosal injury, our data demonstrate 
no substantial control over microbial translocation within 24 months 
of cART, as shown by stable sCD14 and 16s rDNA, and increasing 
EndoCAb. Unexpectedly, despite the strong signal of inefficient gut 
repair, specific clinical indexes of gut permeability (i.e. LAC/MAN and 
calprotectin) were slightly amended selectively in those patients 
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starting cART with advanced gut damage, to possibly reflect the 
unproductive attempt of cART to partially fix mucosal barrier. 
Interestingly, according to our data, the persistence of gut damage on 
2-year suppressive cART seems accompanied the limited effects on 
faecal microbiota composition, featured by modest increase in 
Negativicutes, Selenomonadales, Veillonellaceae, and decrease in 
Lactobacillaceae, Peptococcaceae, Coriobacteriaceae. While some of 
these modifications might be helpful in restoring the balance between 
microbiome and immune system97,98,, other changes, such as the 
appearance of Allisonella (Veillonellaceae family) or Desulfovibrio 
(Desulfovibrionaceae family) genera, might even promote the gut 
damage, possibly worsening disease progression99,100,101. This last 
hypothesis is further supported by our findings of a direct correlation 
between Veillonellaceae family and the marker of enterocyte damage 
I-FABP. Indeed, in line with literature68,80,82,92,102, our cohort of 
chronically HIV-infected individuals maintained a profound dysbiosis, 
characterized by higher faecal α-diversity, a distinct cluster 
separation according to PCoA analysis and a Prevotellaceae-
rich/Bacteroidaceae poor profile, as compared to HIV- individuals. 
The enhancement or impoverishment of some key species has been 
associated with markers of disease progression. In particular, the 
depletion of butyrate-producing bacteria has been associated with 
increased microbial translocation and immune activation58,103, 
supporting the role of specific bacteria population in the HIV 
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pathogenesis. Additionally, our finding of higher faecal α-diversity in 
HIV+ patients seems to be in contrast with previous studies80 and 
may be attributed in part to differences in sexual practices. Indeed, 
MSM were found to have greater faecal microbial differences than 
not-MSM, irrespective of HIV infection76. In our cohort, however, the 
sensitive analysis on HIV+ patients according sexual behaviours  for 
alpha diversity didn’t confirm the differences between MSM and 
heterosexuals at each time point, suggesting that factors other than 
sexual practice might have influenced the microbiota composition. 
However, we could observe only a Prevotellaceae-Succinivibrionaceae-
rich/Bacteroidaceae-poor unbalance after the sensitivity analysis of 
faecal relative abundance at family level in HIV + group; moreover, 
this unbalance seems to partially disappear after the exclusion of 
MSM individuals by the other subjects; in parallel, other significant 
differences appeared between HIV+ heterosexuals and HIV negative 
heterosexuals, with the involvement of other taxa. This way, these 
data suggest a different setting of microbial dysbiosis according to the 
epidemiology of our cohort study with the recommendation to stratify 
in the future any cohorts according to sexual behaviour. The 
evaluation of faecal bacteria compositional changes according to 
different ARV classes indicates a pattern similar to that described in 
the whole cohort. Aside from a small NNRTI-mediated decrease in α-
diversity richness indexes, which is an independent indicator of gut 
microbiome restoration, and has been proposed by Nowak et al.80 to 
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reflect immune reconstitution, we did not highlight marked changes 
according to PI- or INSTI-based combinations, with the exception of 
the changes already described in the whole cohort. Our observations 
are in contrast with recent data showing on one hand a worsening of 
microbial translocation and endothelial damage due to PI-based 
regimens78 and on the other hand a restoration of gut microbiota 
richness following INSTI-containing regimens79, possibly reflecting 
the diverse type of sampling, time on cART and methods used for 
extraction and sequencing of microbial DNA. We should also 
acknowledge that, given the low CD4 count at cART initiation, 19% of 
our cohort was on antibiotic prophylaxis, that was promptly 
interrupted when patients reached a good immune recovery levels 
(generally within the first year). Thus, we could not exclude that part 
of the small modifications observed in gut microbiota composition 
might be mediated by antibiotic suspension. Besides, some cART 
regimens, particularly protease inhibitor-based combinations, could 
induce non-infectious diarrhoea104,105, so it is also possible that the 
changes in microbiome might reflect these side-effects. We next 
focused our research on the characterization of blood microbiota 
composition, given the role of microbial bioproducts within the 
plasma compartment in disease progression47,91. Our analyses 
revealed a different microbial composition between plasma and faecal 
samples, in terms of both α and β diversity, suggesting on one hand a 
selective passage through the gut barrier, possibly mediated by 
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specific immunological carrier, and on the other hand a specific 
immune control over potentially pathogenic microorganism. 
Interestingly, we described higher presence of Proteobacteria phylum 
in contrast to the low intestinal abundance. Given that Proteobacteria 
in blood have been associated with the onset of cardiovascular 
events83, our observations suggest a role of microbiome dysbiosis in 
possibly supporting the development of cardiovascular co-morbidities 
during chronic HIV infection. Several limitations in our study should 
be acknowledged: (i) our inability to study bacterial composition, gut 
damage and immunity at gut mucosal site, that might have shed light 
on the causal relationship between microbiota and immune system 
over the course of cART, (ii) the lack of an extensive analysis of 
microbial function, which would certainly widen the understanding of 
the possible interaction(s) between gut microbial community and 
damage, as well as peripheral immune homeostasis, (iii) the lack of a 
standardized questionnaire on food habits and (iv) the use of a non-
validated drug penetration score into the feces, given the well-known 
distinctive ability of tissue penetrations exerts by the various 
drugs106,107. A further bias in our study might be represented by the 
younger age in control group. It is well known that aging affects gut 
microbiota composition108, however during adulthood (25-50 years) 
the composition tends to be stable109,110, thus we could assume that 
despite the statistical difference in age, the two study groups are 
homogeneous. In conclusion, despite the viro-immunological benefits, 
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long-term effective cART, irrespective of drug classes, resulted in 
persistent gut damage that associates with gut dysbiosis. Besides, 
the finding of a compositional shift in faecal vs plasma microbiota, 
with the enrichment of proteobacteria in peripheral blood, opens new 
perspective on the clinical implication of circulating bacteria and HIV-
associated non-communicable co-morbidities. To our knowledge, this 
is the first study assessing the impact of 24 months of cART on both 
faecal and plasma microbiota composition. Whether the persistence 
of dysbiosis fuels intestinal damage and the consequent microbial 
translocation, or whether the HIV-mediated pro-inflammatory 
environment linked to GI damage and MT promote the dysbiosis still 
need to be elucidated. Further studies are needed to dissect the 
molecular mechanisms behind the interaction of microbiome and 
antiretroviral drugs, possibly taking into account other key players, 
such as the virome111. 
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Table 1. Epidemiological, Clinical and HIV-related features of HIV-infected 
cohort.  
 
T0 T12 T24 p value 
Age, years (IQR) *  38 (31-46) - - - 
Sex males, n (%) °  122 (88) - - - 
Risk factors for HIV 
infection, n (%)°  
 
- - - 
Heterosexual  43 (31)    
MSM  89 (65)    
IDU  6 (4)    
Hepatitis coinfection, n (%) °   - - - 
HCV  8 (5.8)    
HBV  3 (2.1)    
HCV/HBV  2 (1.4)    
Time since 1st HIV diagnosis, 
months (IQR) *  
11.5 (2-40) - - - 
AIDS diagnosis before cART, n 
(%)° 
14 (10.1) 
- - - 
CD4 T-cell count, cell/mmc 
(IQR) * 
312 (210-
385) 
510 (403-
634) 
608 (461-
764) 
<0.0001 
CD4 T-cell, % (IQR) * 19 (15-23) 28 (23-32) 31.5 (25-36) <0.0001 
CD4/CD8 ratio, (IQR) *  
0.31 (0.23-
0.41) 
0.59 (0.42-
0.71) 
0.71 (0.54-
0.88) 
<0.0001 
HIV-RNA, Log cp/ml, (IQR) *   
5.03 (4.55-
5.38) 
1.59 (1.59-
1.59) 
1.59 (1.59-
1.59) 
<0.0001 
Note:*Data are median (IQR). °Data are n (%). IQR: Interquartile range. MSM: men-sex men; IDU: 
intravenous drug users; p value for comparison between T0, T12 and T24. Friedman Test was used. 
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Table 2. Epidemiological, Clinical and HIV-related features of HIV-infected 
cohort.  
 
 HIV + (N=41) 
HIV negative 
(N=15) 
p value 
Age, years (IQR) * 42 (31.5-50.5) 29 (24-33) 0.0017 
Sex, male (n) (%) ° 37 (90) 15 (100) 0.56 
Sexual behaviours MSM, n 
(%) ° 
28 (68,2) 5 (33.3) 0.03 
BMI, n (IQR) * 22,66 (22,02-25,18) 
22,71 (20,98-
24,91) 
0.86 
Vegetarian/vegan diet, n 
subjects (%) ° 
3 (7,3) 0 0.55 
Ongoing antibiotic 
prophylaxis, n (%) ° 
8 (19,5) 0 0.09 
Hepatitis coinfection, n (%) ° 2 (4,8) 0 1 
First cART regimen, n (%)  n/a n/a 
NNRTI-based 25 (61)   
PI-based 9 (22)   
INSTI-based 7 (17)   
 
Note: *Data are median (IQR), statistical analysis Mann-Whitney test °Data are n 
(%), statistical analysis Fisher’s Exact Test. IQR: Interquartile. cART: combination 
of antiretroviral therapy; NNRTI non-nucleoside reverse transcriptase inhibitor; PI 
protease inhibitor; INI: integrase inhibitor. 
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Table 3. Peripheral T-cell phenotypes, microbial translocation and gut damage 
markers in a sub-group of 41 HIV+ patients starting a first cART regimen 
 T0 T12 T24 p 
Viro-immunological 
parameters 
    
CD4 T-cell count, cell/mmc 
(IQR) 
342 (259-431) 
539 (442-
686) 
618 (464-
787) 
<0.0001 
CD8 T-cell count, cell/mmc 
(IQR) 
1000 (874-
1272) 
860 (648-
1124) 
786 (660-
1069) 
0.322 
CD4/CD8 ratio, (IQR) 0,31 (0,24-
0,44) 
0,62 (0,48-
0,78) 
0,73 (0,56-
1,06) 
<0.0001 
HIV-RNA, cp/ml, (IQR)   63734 (22751-
205583) 
<40 <40 <0.0001 
T-cell phenotypes     
CD38+CD8+, % 12 (6-18) 2 (1-3) 2 (1-3) <0.0001 
CD38+CD45R0+CD8+, % 5 (3-12,75) 1 (0-1) 1 (0,50-1) <0.0001 
CD127+CD4+, % 10 (8-12) 17 (12,75-21) 20 (16-25) <0.0001 
CD127+CD8+, % 25 (21-32) 24 (19,75-28) 26 (21-29,5) 0.326 
CD45R0+CD8+, % 21 (16,75-
31,75) 
13 (9-17,25) 13 (9-16,5) <0.0001 
CD45RA+CD8+, % 19 (13,25-23) 19 (14,75-22) 21 (16-25) 0.549 
CD45RA+CD4+, % 6 (3-9) 
7,5 (5,75-
14,25) 
12 (7-18,5) 0.0002 
 
Note: *Data are median (IQR), statistical analysis Friedman Test, with Dunn’s 
multiple comparison. IQR: Interquartile range. 
79 
 
Figure 1. Cohort diagram illustrates the assignment of peripheral blood, urine, 
and stool samples to each analytical method 
We consecutively enrolled 138 HIV-infected patients fulfilling the inclusion criteria. 
All 138 patients underwent blood sampling for immune phenotyping and plasma 
quantification of microbial translocation (sCD14, EndoCAb) and gut damage 
markers (I-FABP). In an unselected sub-group of 41-infected patients, plasma 
samples were used to assess 16S rDNA levels and microbiota composition. In these 
41 patients, we also collected urine for LAC/MAN ratio assessment and stool for 
microbiota analysis and calprotectin quantification. 15 HIV-uninfected healthy 
subjects were enrolled as controls: blood sampling and stool were collected for 
microbiota composition analyses. 
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Figure 2. T-cell activation and maturation following 12 and 24 months of 
suppressive cART 
Detection on plasma of T-cell immune phenotypes by flow cytometry on fresh 
peripheral blood from baseline (naïve, T0) to 12 and 24 months (T12 and T24, 
respectively) after introduction of cART. a-b. significant reduction in activated 
(CD38+) and memory activated (CD38+CD45R0+) CD8 T-cells (both p<0.0001); c-
d. significant increase in CD4- and CD8-expressing CD127 (p<0.0001, p=0.0065 
respectively); e. significant reduction in memory CD45R0+CD8 T-cells (p<0.0001); 
f-g: significant increase in naïve CD45RA+CD8 T-cells (p=0.056) and CD4 T-cells 
(p<0.0001). 
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Figure 3. Microbial translocation (MT) and intestinal damage markers 
following 12 and 24 months of suppressive cART. Quantification of MT and 
intestinal epithelial damage markers by ELISA assay before and after cART 
introduction. sCD14s: soluble CD14 soluble); I-FABP: intestinal fatty acid binding 
protein; EndoCAb: Endotoxin core antibodies. a. no significant differences in sCD14 
(p=0.548), b. significant increase in plasma levels of I-FABP before 24 months of 
suppressive cART (p<0.0001). c. significant increase in circulating EndoCAb levels 
(p<0.0001). 
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Figure 4. Plasma 16S rDNA, gut inflammation and permeability markers 
following 12 and 24 months of suppressive cART 
a-b. No modifications following cART introduction in 16S rDNA plasma levels 
(p=0.72) and sCD14 levels (p=0.102). c-d. Significant increase in EndoCAb 
(p=0.0001) and I-FABP plasma levels (p=0.039). e. Faecal calprotectin was stable 
over time in the entire cohort. f. Significant decrease of calprotectin in HIV+ patients 
with baseline values above the range of normality (i.e. >50µg/g, p=0.018). g-h. 
Permeability test, urinary lactulose-mannitol fractional excretion ratio (LAC/MAN) 
at baseline (T0) and after 12 months the introduction of cART (T12). g. Stable levels 
of LAC/MAN (p=0.657) in the whole cohort. h. HIV+ patients starting cART with 
LAC/MAN ratio greater than the “normality cut-off” 0.05 displayed a significant 
reduction at T12 (p=0.031). 
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Figure 5. Comparison of faecal microbiota composition between HIV-infected 
individuals and HIV- controls 
a. Faecal diversity (α‐diversity) represented as the mean of species diversity per 
sample in each group/class according to Observed, Chao1, Shannon and Simpson at 
baseline. We found a significant increase in HIV+ patients compared to controls 
according to richness parameters (Observed p=0.029; Chao1: p=0.011); no 
differences according to evenness parameters (Shannon p=0.184; Simpson p=0.3033) 
were observed. b. Linear discriminant analysis (LDA) effect size (LEfSe) with LDA 
score>2 log as the cut-off at baseline. We showed only significant results at 
taxonomic level of family with higher abundance in HIV+ patients represented in 
red, while higher families in healthy controls are represented in green.  
 
85 
 
Figure 6. Comparison of faecal microbiota composition between HIV-infected 
individuals MSM and HIV+ heterosexuals individuals (MSW, female and 1 IDU 
patient) 
Faecal diversity (α‐diversity) represented as the mean of species diversity per sample 
in each group/class according Observed, Chao1, Shannon and Simpson at baseline. 
No differences according to all indexes were observed.  
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Figure 7. Faecal relative abundance at each taxonomic level (phylum, class, 
order, family, genus) between HIV-infected individuals and HIV- controls 
Faecal relative abundance, the presented data refer to the comparison between HIV+ 
and HIV- individuals. ↑ indicates increase with significant p values < 0.05, ↓ 
indicates decrease with significant values < 0.05 with exception for taxa 
Bifidobacteriales, Carnobacteriaceae, Acidaminococcus, Bifidobacterium, 
Collinsella and Granulicatella that show trends with p values between 0.05 and 0.07. 
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Figure 8. Faecal relative abundance at baseline for 11 selected faxa family. 
a. Faecal relative abundance, the presented data refer to the comparison between 
HIV+MSM  and HIV+ heterosexuals (which include MSW, female individuals and 1 
IDU MSW subject). b. Faecal relative abundance, the presented data refer to the 
comparison between HIV+ heterosexuals and HIV- heterosexuals. ↑ indicates 
increase with significant p values < 0.05, ↓ indicates decrease with significant values 
< 0.05 with exception for taxa Peptococcaceae and Streptococcaceae that show 
trends with p values between 0.05 and 0.06. 
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Figure 9. Faecal α and β diversity analyses following 24 months of cART 
Faecal α diversity (α‐diversity) represented as the mean of species diversity per 
sample in each group/class according to Observed, Chao1, Shannon and Simpson 
during cART. We failed to find any changes following 24 months of cART, whit 
HIV- maintaining lower richness indexes (Observed p=0.015, Chao1 p=0.002). b. 
Linear discriminant analysis (LDA) effect size (LEfSe) with LDA score>2 log as the 
cut-off between baseline (T0) and after 24 months (T24). Upper part: in green HIV+ 
T24 and in red HIV+ T0. Lower part: in green HIV-, in red HIV+ at T24. c. The 
principal coordinate analyses (PCoA) based on faecal β-diversity results (Jaccard, 
upper; Unweighted Unifrac below, indexes) between HIV+ patients (T0 blue, T12 
red, T24 orange, healthy controls green dots). We observed a cluster separation 
between healthy control and HIV+ irrespective of cART introduction. 
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Figure 10. Faecal relative abundance of bacteria Family and Genus taxa 
following cART introduction  
The presented data refer to taxa at family and genus levels in HIV + patients before 
(T0) and after cART (T12, T24). a. significant increase in Veillonellaceae family 
(p=0.004). b. increasing trend in Desulfovibrionaceae (p=0.092); c-d-e. significant 
decrease, respectively, in Lactobacillaceae, Coriobacteriaceae and Peptococcaceae 
families (p=0.020, p=0.004, p=0.027 respectively). f-g. significant increase in 
Allisonella and Desulfovibrio genera (p=0.004, p=0.037 respectively). h-i-j: 
significant decrease, respectively, in Lactobacillus, Peptococcus and Eggerthella 
genera (p=0.020, p=0.049, p=0.027 respectively).  
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Figure 11. Faecal α diversity Indexes according to different cART regimens 
Comparison of α diversity measures in HIV+ patients during cART subdivided 
according different cART regimens (PI, NNRTI and INSTI based regimens) 
according to Observed (a), Chao1 (b), Shannon (c), Simpson (d): no significant 
differences in PI- and INSTI-based regimens in all measures; no significant 
differences in NNRTI-containing regimens according Shannon and Simpson 
measures, significant decrease only at T12 in NNRTI regimens patients according to 
Observed and Chao1 respectively p=0.038, p=0.006).  
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Figure 12. Faecal relative abundance analyses in HIV+ on NNRTI- or INSTI-
based regimens. Comparison of faecal relative abundance taxa according to cART 
regimens; a. decrease in Coriobacteriaceae following NNRTI-based therapy 
(p=0.018); b. decrease in Peptococcaceae following NNRTI-based therapy (0.027); 
c. increase in Veillonellaceae following NNRTI-based therapy (p=0.029); d. 
decrease in Peptococcaceae following INSTI-based therapy (p=0.003); e. increase in 
Veillonellaceae following INSTI-based therapy (p=0.029); f. increase in Allisonella 
following NNRTI-based therapy (p=0.006). 
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Figure 13. Gut Persistence Score according to different cART regimens. 
Comparison between faecal antiretroviral drug Gut Persistence Score according to 3 
different cART regimens at T12 (a), at T24 (b): no significant differences, Kruskal-
Wallis test. 
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Figure 14. Faecal and Plasma Phylum Distribution 
a-b. The relative abundance of Actinobacteria and Proteobacteria phyla was higher 
in plasma than in feces in all the study groups. c-d.  The relative abundance of 
Firmicutes and Bacteroidetes phyla was lower in plasma, as compared to feces, in 
both healthy controls and HIV-infected patients prior and after cART introduction. 
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Figure 15. Plasma microbiota composition: α and β diversity analyses 
Plasma α diversity (α‐diversity) represented as the mean of species diversity per 
sample in each group/class according to a. Observed b. Chao1 c. Shannon and d. 
Simpson before (T0) and after12 (T12) and 24 (T24) months of cART, vs HIV-
negative healthy controls. No significant differences following cART initiation were 
found. On the opposite, significant differences between HIV+ and HIV- controls at 
all time points, according to evenness parameters (Shannon p=0.020; Simpson 
p=0.009) were observed. e-f. The principal coordinate analyses (PCoA) based on 
plasma β-diversity results revealed no significant differences. g-h. Linear 
discriminant analysis (LDA) effect size (LEfSe) with LDA score>2 log as the cut-
off. g. HIV- controls (green), HIV+ patients T24 (red): higher Sphingobacteriales 
(p<0.0001), yet lower Chitinophagaceae (p=0.001), Cytophagales (p<0.0001) 
Sphingomonadales (p=0.01) and Enterobacteriales (p=0.029) in HIV+ patients h. 
HIV+ T0 (green), HIV+ T24 (red): slight variations of Staphylococcaceae, 
Sphingomonadaceae and Pseudomonadaceae families following 24 months of 
suppressive cART. 
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